Bortezomib Combination Therapy in Multiple Myeloma

This publication has 47 references indexed in Scilit:

• From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of Rapamycin
  Journal of Clinical Oncology, 2012
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
  Leukemia, 2011
• Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial
  Blood, 2011
• Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
  British Journal of Haematology, 2010
• Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
  Blood, 2010
• Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
  Leukemia, 2010
• DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma
  Annals of Hematology, 2009
• Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial
  Leukemia, 2009
• Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
  New England Journal of Medicine, 2008
• Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
  British Journal of Haematology, 2008